Introduction
Pre-clinical Development
As a leader in the field of life science, Alzheimacy has established an integrated antibody discovery and engineering platform. Our comprehensive antibody development capabilities include but are not limited to target discovery and validation, surface display technologies and antibody library screening, antibody humanization and affinity maturation, pilot production of therapeutic antibodies, efficacy study and safety evaluation of therapeutic antibodies.
In the process of antibody discovery, our hybridoma, phage display, B cell sorting, and other technologies give us strong support. Our transgenic design and technology allow for potent antibody gene rearrangement, class switching, and somatic hypermutation, which is the foundation for yielding diversified antibody pools. Moreover, we support the development of antibodies at the extra small size that allows for increased flexibility, better penetration (i.e. cross the blood-brain barrier), higher conformational epitope accessibility, and easier production. Long-term experience in the creation and assessment of animal models supports our preclinical assessment for AD therapeutic antibodies.
As a leader in the field of life science, Alzheimacy has established an integrated antibody discovery and engineering platform. Our comprehensive antibody development capabilities include but are not limited to target discovery and validation, surface display technologies and antibody library screening, antibody humanization and affinity maturation, pilot production of therapeutic antibodies, efficacy study and safety evaluation of therapeutic antibodies.
In the process of antibody discovery, our hybridoma, phage display, B cell sorting, and other technologies give us strong support. Our transgenic design and technology allow for potent antibody gene rearrangement, class switching, and somatic hypermutation, which is the foundation for yielding diversified antibody pools. Moreover, we support the development of antibodies at the extra small size that allows for increased flexibility, better penetration (i.e. cross the blood-brain barrier), higher conformational epitope accessibility, and easier production. Long-term experience in the creation and assessment of animal models supports our preclinical assessment for AD therapeutic antibodies.
Contact Info
Address:
45-1 Ramsey Road, Shirley, New York 11967, USA
New York
11967
United States
New York
11967
United States
Tel:
1-6316197922
Website:
https://www.creativebiomart.net/alzheimacy/therapeutics/therapeutic-antibody/
Hours of operation
| From | To | From | To | From | To | ||
|---|---|---|---|---|---|---|---|
| Monday | Open | ||||||
| Tuesday | Open | ||||||
| Wednesday | Open | ||||||
| Thursday | Open | ||||||
| Friday | Open | ||||||
| Saturday | Open | ||||||
| Sunday | Open | ||||||
